Heart Test Laboratories I... (HSCS)
Heart Test Laboratories Statistics
Share Statistics
Heart Test Laboratories has 1.08M shares outstanding. The number of shares has increased by 64.87% in one year.
Shares Outstanding | 1.08M |
Shares Change (YoY) | 64.87% |
Shares Change (QoQ) | 10.26% |
Owned by Institutions (%) | 2.89% |
Shares Floating | 933.58K |
Failed to Deliver (FTD) Shares | 216 |
FTD / Avg. Volume | 1.46% |
Short Selling Information
The latest short interest is 54.95K, so 5.61% of the outstanding shares have been sold short.
Short Interest | 54.95K |
Short % of Shares Out | 5.61% |
Short % of Float | 6.22% |
Short Ratio (days to cover) | 2.41 |
Valuation Ratios
The PE ratio is -0.49 and the forward PE ratio is -0.49. Heart Test Laboratories's PEG ratio is 0.
PE Ratio | -0.49 |
Forward PE | -0.49 |
PS Ratio | 175.12 |
Forward PS | 0.7 |
PB Ratio | 0.45 |
P/FCF Ratio | -0.53 |
PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Heart Test Laboratories.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.2, with a Debt / Equity ratio of 0.14.
Current Ratio | 4.2 |
Quick Ratio | 3.84 |
Debt / Equity | 0.14 |
Debt / EBITDA | -0.17 |
Debt / FCF | -0.17 |
Interest Coverage | -17.81 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $1.24K |
Profits Per Employee | $-440.35K |
Employee Count | 15 |
Asset Turnover | 0 |
Inventory Turnover | 0.01 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -67.26% in the last 52 weeks. The beta is 2.73, so Heart Test Laboratories's price volatility has been higher than the market average.
Beta | 2.73 |
52-Week Price Change | -67.26% |
50-Day Moving Average | 3.24 |
200-Day Moving Average | 3.49 |
Relative Strength Index (RSI) | 64.01 |
Average Volume (20 Days) | 14.76K |
Income Statement
In the last 12 months, Heart Test Laboratories had revenue of 18.6K and earned -6.61M in profits. Earnings per share was -18.74.
Revenue | 18.6K |
Gross Profit | 12.52K |
Operating Income | -6.31M |
Net Income | -6.61M |
EBITDA | -6.16M |
EBIT | -6.25M |
Earnings Per Share (EPS) | -18.74 |
Balance Sheet
The company has 5.81M in cash and 1.04M in debt, giving a net cash position of 4.77M.
Cash & Cash Equivalents | 5.81M |
Total Debt | 1.04M |
Net Cash | 4.77M |
Retained Earnings | -67.36M |
Total Assets | 5.7M |
Working Capital | 57.63M |
Cash Flow
In the last 12 months, operating cash flow was -6.07M and capital expenditures -125.27K, giving a free cash flow of -6.2M.
Operating Cash Flow | -6.07M |
Capital Expenditures | -125.27K |
Free Cash Flow | -6.2M |
FCF Per Share | -17.57 |
Margins
Gross margin is 67.31%, with operating and profit margins of -33901.99% and -35511.87%.
Gross Margin | 67.31% |
Operating Margin | -33901.99% |
Pretax Margin | -35511.87% |
Profit Margin | -35511.87% |
EBITDA Margin | -33096.75% |
EBIT Margin | -33901.99% |
FCF Margin | -33308.9% |
Dividends & Yields
HSCS does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for HSCS is $14, which is 300% higher than the current price. The consensus rating is "Buy".
Price Target | $14 |
Price Target Difference | 300% |
Analyst Consensus | Buy |
Analyst Count | 3 |
Stock Splits
The last stock split was on May 17, 2024. It was a backward split with a ratio of 1:100.
Last Split Date | May 17, 2024 |
Split Type | backward |
Split Ratio | 1:100 |
Scores
Altman Z-Score | -19534.18 |
Piotroski F-Score | 0 |